Bright Minds Moves Into Clinical Development Stage Following Positive Toxicity Results
Drug development continues for the Bright Minds Biosciences (CSE: DRUG) lead product. The firm this morning published positive results from
Read more
Bright Minds Biosciences
Bright Minds Bioscience: A Deep Dive
Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright
Read more
Bright Minds Bioscience Approved For Nasdaq Listing
There’s another Canadian firm set to trade on the Nasdaq market. Bright Minds Bioscience (CSE: DRUG) this morning announced that
Read more
Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022
Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing
Read more
Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm
Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer
Read more
Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive
On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising
Read more
Bright Minds Biosciences Proprietary Compound Shows Reduction Of Seizures In Pre-Clinical Studies
Bright Minds Biosciences (CSE: DRUG) this morning announced preliminary results from an ongoing study being conducted by the firm. The
Read more
Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive
Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom is VP of Discovery at
Read more
Bright Minds Applies For Nasdaq Listing
Bright Minds Biosciences (CSE: DRUG) has an eye for the US big boards. The company this morning announced that it
Read more
Psychedelics: The Eight Capital Primer
Eight Capital recently produced a primer on the psychedelic sector saying that the companies are “poised to fill a growing
Read more